Literature DB >> 30971814

Optical coherence tomography angiography of types 1 and 2 choroidal neovascularization in age-related macular degeneration during anti-VEGF therapy: evaluation of a new quantitative method.

Henrik Faatz1, Marie-Louise Farecki2, Kai Rothaus2, Frederic Gunnemann2, Matthias Gutfleisch2, Albrecht Lommatzsch2,3, Daniel Pauleikhoff2,3.   

Abstract

PURPOSE: The aim of this pilot study was to test whether mathematical parameters of the vascular morphology of choroidal neovascularization (CNV) can be used as biomarkers and to investigate how these parameters change during anti-vascular endothelial growth factor (VEGF) therapy.
METHODS: Treatment-naive CNV in exudative age-related macular degeneration (AMD) was diagnosed in 28 patients. OCT-angiography (OCT-A) (Avanti/FA Optovue) performed before and after anti-VEGF therapy. The OCT-A data sets were exported to an external image processing program and vessel skeletonization was accomplished by means of edge detection. Based on this technique the total vessel length, the number of segments and the fractal dimension (FD) of the CNV were calculated before and after therapy. The results were compared with other clinical parameters such as VA and central retinal thickness (RT).
RESULTS: The total vessel length of the CNV was significantly reduced by anti-VEGF-therapy (mean value 652 pixels vs. 397 pixels; p < 0.0001), as well as the number of individual vessel segments of the CNV (mean value 117 vs. 76; p < 0.0001). The FD of the CNV also decreased significant reduction during therapy (mean 1.23 vs. 1.16, p < 0.0001). The changes in these parameters during treatment corresponded with an increase in VA and a reduction in RT.
CONCLUSION: This pilot study demonstrates that the vascular pattern of CNV in AMD can be visualized and described using mathematical parameters of OCT-A. The changes during therapy correlate significantly with established "activity" parameters of CNV, so changes in these parameters (especially FD) may represent additional CNV "activity" biomarkers.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30971814      PMCID: PMC7002694          DOI: 10.1038/s41433-019-0429-8

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  18 in total

1.  Characteristics of type 1 and 2 CNV in exudative AMD in OCT-Angiography.

Authors:  Marie-Louise Farecki; Matthias Gutfleisch; Henrik Faatz; Kai Rothaus; Britta Heimes; Georg Spital; Albrecht Lommatzsch; Daniel Pauleikhoff
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-02-23       Impact factor: 3.117

2.  OCT angiography and sequential quantitative analysis of type 2 neovascularization after ranibizumab therapy.

Authors:  L Kuehlewein; S R Sadda; D Sarraf
Journal:  Eye (Lond)       Date:  2015-05-15       Impact factor: 3.775

3.  Type 1 Choroidal Neovascularization Lesion Size: Indocyanine Green Angiography Versus Optical Coherence Tomography Angiography.

Authors:  Eliana Costanzo; Alexandra Miere; Giuseppe Querques; Vittorio Capuano; Camille Jung; Eric H Souied
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-07-01       Impact factor: 4.799

4.  DETECTION OF NONEXUDATIVE CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION WITH OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY.

Authors:  Neal V Palejwala; Yali Jia; Simon S Gao; Liang Liu; Christina J Flaxel; Thomas S Hwang; Andreas K Lauer; David J Wilson; David Huang; Steven T Bailey
Journal:  Retina       Date:  2015-11       Impact factor: 4.256

5.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Authors:  David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

6.  [Early treatment of exudative age-related macular degeneration with ranibizumab (Lucentis®): the key to success].

Authors:  E Matthé; D Sandner
Journal:  Ophthalmologe       Date:  2011-03       Impact factor: 1.059

7.  Optical Coherence Tomography Angiography Signs of Vascular Abnormalization With Antiangiogenic Therapy for Choroidal Neovascularization.

Authors:  Richard F Spaide
Journal:  Am J Ophthalmol       Date:  2015-04-14       Impact factor: 5.258

8.  Optical Coherence Tomography Angiography of Type 1 Neovascularization in Age-Related Macular Degeneration.

Authors:  Laura Kuehlewein; Mayank Bansal; Tamara L Lenis; Nicholas A Iafe; SriniVas R Sadda; Marco A Bonini Filho; Talisa E De Carlo; Nadia K Waheed; Jay S Duker; David Sarraf
Journal:  Am J Ophthalmol       Date:  2015-07-09       Impact factor: 5.258

9.  Optical coherence tomography angiography during follow-up: qualitative and quantitative analysis of mixed type I and II choroidal neovascularization after vascular endothelial growth factor trap therapy.

Authors:  Gabriel Coscas; Marco Lupidi; Florence Coscas; Catherine Français; Carlo Cagini; Eric H Souied
Journal:  Ophthalmic Res       Date:  2015-07-17       Impact factor: 2.892

10.  LONGITUDINAL OPTICAL COHERENCE TOMOGRAPHY-ANGIOGRAPHY STUDY OF TYPE 2 NAIVE CHOROIDAL NEOVASCULARIZATION EARLY RESPONSE AFTER TREATMENT.

Authors:  Bruno Lumbroso; Marco Rispoli; Maria Cristina Savastano
Journal:  Retina       Date:  2015-11       Impact factor: 4.256

View more
  12 in total

1.  Evaluation of the Effect of Religious Fasting on Retinal Vessel Density and Retinal Thickness Using Optical Coherence Tomography Angiography.

Authors:  Saeed Shokoohi-Rad; Nasser Shoeibi; Mohammad Ghasemi Nour; Elham Bakhtiari
Journal:  Neuroophthalmology       Date:  2021-11-04

2.  Quantitative Comparison of the Vascular Structure of Macular Neovascularizations Between Swept-Source and Spectral-Domain Optical Coherence Tomography Angiography.

Authors:  Henrik Faatz; Kai Rothaus; Martin Ziegler; Marius Book; Claudia Lommatzsch; Georg Spital; Matthias Gutfleisch; Daniel Pauleikhoff; Albrecht Lommatzsch
Journal:  Clin Ophthalmol       Date:  2020-10-09

Review 3.  Quantitative optical coherence tomography angiography: A review.

Authors:  Xincheng Yao; Minhaj N Alam; David Le; Devrim Toslak
Journal:  Exp Biol Med (Maywood)       Date:  2020-01-20

Review 4.  Imaging endpoints for clinical trials in MacTel type 2.

Authors:  Daniel Pauleikhoff; Laurenz Pauleikhoff; Emily Y Chew
Journal:  Eye (Lond)       Date:  2021-08-13       Impact factor: 3.775

5.  Correlation of retinal alterations with vascular structure of macular neovascularisation in swept-source optical coherence tomography angiography in age-related macular degeneration.

Authors:  Henrik Faatz; Kai Rothaus; Martin Ziegler; Marius Book; Georg Spital; Britta Heimes-Bussmann; Daniel Pauleikhoff; Albrecht Lommatzsch
Journal:  Int Ophthalmol       Date:  2022-01-13       Impact factor: 2.029

6.  Vascular density in age-related macular degeneration after one year of antiVEGF treatment with treat-and-extend and fixed regimens.

Authors:  Miklós D Resch; Anikó Balogh; Gábor Gy Deák; Zoltán Z Nagy; András Papp
Journal:  PLoS One       Date:  2020-02-26       Impact factor: 3.240

7.  Retinal vascular metrics difference by comparison of two image acquisition modes using a novel OCT angiography prototype.

Authors:  Luca Di Antonio; Pasquale Viggiano; Giada Ferro; Lisa Toto; Rossella D'Aloisio; Annamaria Porreca; Marta Di Nicola; Rodolfo Mastropasqua
Journal:  PLoS One       Date:  2020-12-01       Impact factor: 3.240

Review 8.  Plexus-specific retinal vascular anatomy and pathologies as seen by projection-resolved optical coherence tomographic angiography.

Authors:  Tristan T Hormel; Yali Jia; Yifan Jian; Thomas S Hwang; Steven T Bailey; Mark E Pennesi; David J Wilson; John C Morrison; David Huang
Journal:  Prog Retin Eye Res       Date:  2020-07-24       Impact factor: 21.198

9.  Changes in the OCT angiographic appearance of type 1 and type 2 CNV in exudative AMD during anti-VEGF treatment.

Authors:  Henrik Faatz; Marie-Louise Farecki; Kai Rothaus; Matthias Gutfleisch; Daniel Pauleikhoff; Albrecht Lommatzsch
Journal:  BMJ Open Ophthalmol       Date:  2019-12-10

10.  Combined quantitative and qualitative optical coherence tomography angiography biomarkers for predicting active neovascular age-related macular degeneration.

Authors:  Cherng-Ru Hsu; Tso-Ting Lai; Yi-Ting Hsieh; Tzyy-Chang Ho; Chung-May Yang; Chang-Hao Yang
Journal:  Sci Rep       Date:  2021-09-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.